5 The 2018 update focused heavily on the use of glucose-lowering agents to mitigate cardiovascular and renal risks in the context of meeting individualized glycemic goals
poorer early language & attention problems Golding et al., 2023 (ALSPAC, UK) Disadvantage in later scholastic performance Alemany et al., 2021 (EClinicalMedicine, 6 cohorts) Pooled evidence ASD/ADHD risk Bauer et al., 2018 (Env Int, Systematic Review) Stronger associations with longer duration of use Just bc its not 1:1 causal, does not make it safe
The most common side effects of receiving GTLIVE 600MG INJECTION are anorexia (eating disorder), nausea, vomiting, and/or rash
Chaouhan HS, Vinod C, Mahapatra N, Yu S-H, Wang I-K, Chen K-B, et al
Safety, Compliance, and Research Protocols This product is strictly for laboratory research use only and is not FDA-approved for human consumption
Shotsy is available on iPhone, iPad, Mac, and Android